Ascentage Pharma Advances Global Phase III Trial for Lisaftoclax in Higher-Risk MDS Treatment

Ascentage Pharma has announced the commencement of patient enrollment for its GLORA-4 Phase III trial, evaluating lisaftoclax in combination with azacitidine for treating newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS). This trial, cleared by both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), represents a critical step toward addressing the lack of targeted therapies for HR-MDS, a condition with limited treatment options and poor prognosis.

The GLORA-4 study is a multi-region, multi-center, randomized, double-blind Phase III trial designed to assess the efficacy and safety of lisaftoclax combined with AZA versus placebo plus AZA. Lisaftoclax, a novel Bcl-2 inhibitor, has shown promising results in earlier studies, with an overall response rate of 75% in treatment-naïve MDS patients, significantly higher than the current standard of care. The trial's global nature, including sites in China, the U.S., and Europe, aims to accelerate the drug's development and potential market authorization.

Higher-risk MDS is a challenging condition, particularly prevalent in the elderly, with a median age of diagnosis at 70 years. Current treatments, such as hypomethylating agents (HMA) and allogeneic hematopoietic stem cell transplantation (allo-HSCT), offer limited efficacy and are associated with significant side effects and mortality rates. The introduction of lisaftoclax could revolutionize the treatment landscape for HR-MDS, offering a much-needed targeted therapy option.

Dr. Yifan Zhai, Chief Medical Officer of Ascentage Pharma, highlighted the importance of this trial, noting the urgent need for innovative treatments in HR-MDS. The study's success could establish lisaftoclax as the first Bcl-2 inhibitor approved for first-line treatment of HR-MDS, marking a significant milestone in oncology research.

For more information on the GLORA-4 trial, visit https://ascentage.com/.